Breaking News

ST Pharm to Expand Oligonucleotide Facility

Will invest $126 million thru 2025 in second oligonucleotide plant with four to six large production lines.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ST Pharm Co. Ltd., an API CDMO in the Republic of Korea, plans to build a second oligonucleotide manufacturing plant to expand production facilities and to accommodate the rapidly growing oligonucleotide therapeutics market.   ST Pharm will invest $126 million thru 2025 at its Banwol campus located in Ansan, with the construction of the second oligonucleotide plant with four to six large production lines.   The second oligonucleotide manufacturing plant will be designed to maximize efficienc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters